kidney cancer Archives -

Kidney cancer care is rapidly approaching a tipping point in the UK. Despite being one of the 12

The challenges and opportunities for kidney cancer care recovery

https://pharmaphorum.com/oncology/the-challenges-and-opportunities-for-kidney-cancer-care-recovery/

Oncology/ Patients/ R&D/ Views & Analysis/ Views & Analysis/ Views & Analysis/ Views and analysis

Putting patient perspectives at the heart of kidney cancer research

mike.hammerton@pharmaphorum.com cancer, Ipsen, kidney cancer, patients, R&D, renal cell carcinoma, RWE 0 Comment

Commissioned by Ipsen. Ipsen’s Steven Hildemann looks at how we can harness the power of patient perspectives in

Putting patient perspectives at the heart of kidney cancer research

https://pharmaphorum.com/patients/patient-perspectives-kidney-cancer-research/

Market Access/ News/ News

Scotland backs Cabometyx combo for kidney cancer, amid stalled NICE review

Phil Taylor Bristol-Myers Squibb, Cabometyx, HEOR, immuno-oncology, Ipsen, kidney cancer, market access, Oncology, Opdivo, SMC 0 Comment

Patients in Scotland with newly-diagnosed advanced kidney cancer can now access a therapy combining Bristol-Myers Squibb’s immunotherapy Opdivo

Scotland backs Cabometyx combo for kidney cancer, amid stalled NICE review

https://pharmaphorum.com/news/scotland-backs-cabometyx-combo-for-kidney-cancer-amid-stalled-nice-review/

News/ News/ News/ Oncology/ R&D

Merck’s Keytruda demonstrates adjuvant use in kidney cancer

Catherine Longworth Keytruda, kidney cancer, Merck and Co, Oncology 0 Comment

Merck & Co has announced interim data from its pivotal Phase 3 KEYNOTE-564 trial evaluating immunotherapy Keytruda for

Merck’s Keytruda demonstrates adjuvant use in kidney cancer

https://pharmaphorum.com/news/mercks-keytruda/

News/ News/ Oncology

BMS gets an important win for Opdivo combination in kidney cancer

Phil Taylor Bristol-Myers Squibb, Exelixis, immuno-oncology, kidney cancer, Merck & Co, Oncology, Opdivo, Pfizer, renal cell carcinoma 0 Comment

Bristol-Myers Squibb has staked another claim to the first-line kidney cancer market, with impressive new data for the

BMS gets an important win for Opdivo combination in kidney cancer

https://pharmaphorum.com/news/bms-gets-an-important-win-for-opdivo-combination-in-kidney-cancer/

News/ News/ Oncology

BMS builds case for long-term use of Opdivo in kidney cancer

Richard Staines Bristol-Myers Squibb, cancer, kidney cancer, Merck & Co, Merck KGaA, Opdivo, Pfizer, renal cell carcinoma 0 Comment

Bristol-Myers Squibb has unveiled long-term results from its immunotherapy Opdivo in the most common form of kidney cancer,

BMS builds case for long-term use of Opdivo in kidney cancer

https://pharmaphorum.com/news/bms-builds-case-for-long-term-use-of-opdivo-in-kidney-cancer/

News/ News/ Oncology

NICE rejects MSD/Pfizer’s combination in untreated kidney cancer

Richard Staines cancer, kidney cancer, market access, MSD, NICE, Pfizer, renal cell carcinoma 0 Comment

NICE said “no” to NHS funding for a combination of MSD’s Keytruda (pembrolizumab) immunotherapy and Pfizer’s Inlyta (axitinib)

NICE rejects MSD/Pfizer’s combination in untreated kidney cancer

https://pharmaphorum.com/news/nice-rejects-msd-pfizers-combination-in-untreated-kidney-cancer/

News/ News/ Oncology

Immunicum continues cell therapy trials after positive kidney cancer readout

Richard Staines kidney cancer, Oncology, R&D 0 Comment

Sweden’s Immunicum has announced detailed results from its mid-stage trial of its oncology cell-based immunotherapy ilixadencel, which it

Immunicum continues cell therapy trials after positive kidney cancer readout

https://pharmaphorum.com/news/immunicum-to-push-on-with-immunotherapy/

News/ News/ Oncology

Keytruda combo cleared as first-line kidney cancer treatment in EU

Phil Taylor immuno-oncology, Inlyta, Keytruda, kidney cancer, Merck & Co, Pfizer 0 Comment

Merck & Co/MSD’s Keytruda has added first-line kidney cancer treatment to its ever-lengthening list of approved uses in

Keytruda combo cleared as first-line kidney cancer treatment in EU

https://pharmaphorum.com/news/keytruda-combo-cleared-first-line-kidney-cancer-treatment-eu/

Trending

kidney cancer

Login